CN111518785A - 一种高活性piggyBac转座酶及其应用 - Google Patents
一种高活性piggyBac转座酶及其应用 Download PDFInfo
- Publication number
- CN111518785A CN111518785A CN201910105753.1A CN201910105753A CN111518785A CN 111518785 A CN111518785 A CN 111518785A CN 201910105753 A CN201910105753 A CN 201910105753A CN 111518785 A CN111518785 A CN 111518785A
- Authority
- CN
- China
- Prior art keywords
- piggybac
- piggybac transposase
- transposase
- carrying
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008579 Transposases Human genes 0.000 title claims abstract description 74
- 108010020764 Transposases Proteins 0.000 title claims abstract description 74
- 230000000694 effects Effects 0.000 title claims abstract description 23
- 150000001413 amino acids Chemical group 0.000 claims abstract description 14
- 235000001014 amino acid Nutrition 0.000 claims abstract description 13
- 230000017105 transposition Effects 0.000 claims abstract description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004471 Glycine Substances 0.000 claims abstract description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004473 Threonine Substances 0.000 claims abstract description 4
- 235000018417 cysteine Nutrition 0.000 claims abstract description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229930182817 methionine Natural products 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 230000002950 deficient Effects 0.000 claims description 24
- 230000009261 transgenic effect Effects 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 108091026890 Coding region Proteins 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 230000008439 repair process Effects 0.000 claims description 8
- 108010076282 Factor IX Proteins 0.000 claims description 5
- 229940105774 coagulation factor ix Drugs 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 238000010276 construction Methods 0.000 claims description 4
- 108091061960 Naked DNA Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 239000013603 viral vector Substances 0.000 description 10
- 230000035772 mutation Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000013831 Coagulation factor IX Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明的目的在于提供一种高活性piggyBac转座酶及其应用。一种piggyBac转座酶，其特征在于：氨基酸位点165位的甘氨酸改变为半胱氨酸，或氨基酸位点282位的蛋氨酸改变为苏氨酸，或这两个位点同时发生上述改变。本发明的高活性piggyBac转座酶，提高了piggyBac转座子系统的转座效率。
Description
技术领域
本发明涉及一种高活性piggyBac转座酶，本发明还涉及piggyBac转座酶的应用，属于生物技术领域。
背景技术
基因转移技术在基因治疗和非人转基因动物建立中被广泛使用。常用的介导稳定转基因的媒介包括：病毒载体，如：反转录病毒、慢病毒和腺相关病毒；和非病毒载体，如：PhiC31整合酶和各类转座子系统。基于病毒载体的转基因技术在实际操作中涉及病毒包装，对操作者和操作环境有较高的技术与安全要求。此外，在哺乳动物体内使用病毒载体介导转基因可能导致免疫反应，存在安全和排斥问题。非病毒载体是一种相对安全和简便的转基因媒介。但现有的非病毒载体普遍存在效率低下的问题。
piggyBac转座子系统是现有在动物转基因应用中效率最高的非病毒载体。piggyBac转座子早先于粉斑夜蛾Trichoplusia ni的基因组中被发现，大小为2472bp，两端包含反向末端重复序列ITR，中间包含编码594个氨基酸的转座酶。piggyBac转座子类属于DNA转座子，通过剪切和粘贴机制可以由位于外源DNA或内源基因组的起始位点切离，并随机插入基因组中的另一位点。piggyBac转座子插入靶位点的序列为四核苷酸的TTAA。piggyBac转座子在切离TTAA时一般不会改变原位点及原位点的附近序列，即所谓无痕转座。2005年，复旦大学研究人员发现，piggyBac转座子能在体外培养哺乳动物细胞及小鼠基因组中转座，并能携带至多10kb的外源基因而不影响其转座效率。基于piggyBac转座子能介导随机插入，无痕转座，携带大片段外源基因，以及在哺乳动物细胞中转座的特点，其在基因治疗、非人转基因哺乳动物建立和随机插入突变引入等邻域中的潜在应用有待被进一步开发，而提高piggyBac转座子系统的效率在这其中至关重要。
发明内容
本发明的目的在于提供一种高活性piggyBac转座酶及其应用。
本发明采用了如下技术方案：
一种piggyBac转座酶，其特征在于：氨基酸位点165位的甘氨酸改变为半胱氨酸，或氨基酸位点282位的蛋氨酸改变为苏氨酸，或这两个位点同时发生上述改变。
本发明还提供上述piggyBac转座酶，在制备介导缺陷piggyBac转座子转座插入HEK293细胞基因组的试剂中的应用。
本发明还提供上述piggyBac转座酶在制备基因整合试剂中的应用。
本发明还提供上述piggyBac转座酶，在制备无痕基因修复的试剂中的应用，其特征在于：piggyBac转座酶为PBase(G165C/M282T)。
本发明还提供上述piggyBac转座酶，在建立转基因非人动物中的应用，其特征在于：包括将编码新型高活性piggyBac转座酶PBase(G165C/M282T)和携带Katshka远红外荧光蛋白编码序列的piggyBac转座子同时显微注射入小鼠受精卵内的步骤。
本发明还提供上述piggyBac转座酶，在制备建立转基因非人动物的试剂中的应用。
进一步，piggyBac转座酶，在制备建立转基因非人动物的试剂中的应用，其中，试剂中还包含携带Katshka远红外荧光蛋白编码序列的piggyBac转座子。
本发明还提供上述高活性piggyBac转座酶在制备基因代偿治疗所需试剂中的应用，其特征在于：包括制备携带新型高活性piggyBac转座酶与携带凝血因子IX的缺陷piggyBac转座子的裸DNA的步骤。
发明的有益效果
本发明的高活性piggyBac转座酶，提高了piggyBac转座子系统的转座效率，从而使得piggyBac转座子能更高效地被用于基因治疗、稳定转基因细胞系和转基因非人动物建立、以及在培养细胞和非人动物基因组中引入插入突变。
附图说明
图1是本发明高活性piggyBac转座酶PBase的氨基酸序列示意图。
图2是筛选获得高活性piggyBac转座酶的技术方案设计图。
图3是本发明高活性piggyBac转座酶的一个实施例。
图4是本发明高活性piggyBac转座酶应用于基因治疗的一个实施例。
图5是本发明高活性piggyBac转座酶应用于基因治疗的另一个实施例。
图6是本发明高活性piggyBac转座酶应用于建立转基因非人动物的一个实施例。
具体实施方式
以下通过具体实施方式来详细说明本发明的技术方案。
本发明提高piggyBac转座酶转座效率所采用的实施方式是利用易错聚合酶链式反应error-prone PCR对野生型piggyBac转座酶的编码序列进行随机突变，获得大量携带不同氨基酸非保守改变的piggyBac转座酶突变体。
获得piggyBac转座酶突变体的具体步骤是：
1)利用引物PBaseF序列见SEQ ID No.1和PBaseR序列见SEQ ID No.2对野生型piggyBac转座酶序列运用易错聚合酶链式反应进行扩增，反应体系如表1所示。反应条件为：变性95℃，1分钟；退火60℃，1分钟；延伸72℃，3分钟；循环数为5。
| SEQ No. | 序列 |
| 1 | GGAGAATTCGCCACCATGGGATGTTCTTTAGAC |
| 2 | GGCGAATTCTCAGAAACAACTTTGGCACATATC |
2)将扩增得到的产物用EcoRI酶进行酶切，并装入pCAG-EGFP质粒(购自Addgene)的两个EcoRI位点间，从而获得携带piggyBac转座酶突变体的表达载体。
表1
上述实施方式中所涉及的质粒抽提，质粒转化，大肠杆菌培养，酶切和连接为本领域人员所熟知的实验。常规实验条件可参照M.R.格林和J.萨姆布鲁克编著的《分子克隆实验指南》第四版。
1.筛选高活性piggyBac转座酶
在一优选实施例中，将携带非保守氨基酸改变的piggyBac转座酶与携带Blasticidine(Blast)抗药筛选标记的缺陷piggyBac转座子的核酸各1μg与10μLLipofectamine 2000脂质体(购自Invitrogen)混合于250μL Opti-MEM培养基中。将核酸脂质体混合液加入含有4x105单层培养的HEK293细胞的培养皿内。
在一些备选的实施例中，携带非保守氨基酸改变的piggyBac转座酶与携带抗药筛选标记的缺陷piggyBac转座子的核酸可以通过磷酸钙转染、聚乙二醇-聚乙烯亚胺共聚物转染、或电穿孔转染导入体外培养的动物细胞。
在另一些备选的实施例中，携带非保守氨基酸改变的piggyBac转座酶与携带抗药筛选标记的缺陷piggyBac转座子的核酸可以被装入病毒载体。这里的病毒载体包括但不限于腺病毒、腺相关病毒，反转录病毒，慢病毒和单纯疱疹病毒。随后，对携带转座子系统的病毒进行包装，并感染导入靶细胞。
将成功被导入转座子的HEK293细胞用胰酶处理收集，并做1：10稀释培养，同时在培养基中加入5μg/ml Blasticidine(购自Invitrogen)，药物筛选两周，得到携带稳定缺陷piggyBac转座子插入的细胞克隆。用10％中性缓冲福尔马林固定液固定细胞，并用台盼蓝染色对细胞克隆进行计数。筛选获得高活性piggyBac转座酶的技术方案设计图如图2所示，转座酶的活性决定了细胞克隆数。
如图1所示，本实施方式筛选得到的新型高活性piggyBac转座酶为氨基酸位点165位的甘氨酸改变为半胱氨酸，G165C，GGT变为TGT，见SEQ ID No.3，或氨基酸位点282位的蛋氨酸改变为苏氨酸，M282T，ATG变为TTG，见SEQ ID No.4，或这两个位点同时发生上述改变G165C/M282T，见SEQ ID No.5。
如图3所示，本发明的新型高活性piggyBac转座酶PBase(G165C)、PBase(M282T)和PBase(G165C/M282T)的转座效率高于野生型piggyBac转座酶，介导缺陷piggyBac转座子高效转座插入HEK293细胞基因组，产生更多携带稳定缺陷piggyBac转座子插入的细胞克隆。
上述高活性piggyBac转座酶PBase，G165C/M282T的编码序列可以根据特定动物细胞类型选择优选密码子。
在一个针对小鼠细胞的优选例中，新型高活性piggyBac转座酶的编码序列为SEQID No.6。
在一个针对大鼠细胞的优选例中，新型高活性piggyBac转座酶的编码序列为SEQID No.7。
在一个针对人细胞的优选例中，新型高活性piggyBac转座酶的编码序列为SEQ IDNo.8。
2.高活性piggyBac转座酶的应用
本实施方式中高活性piggyBac转座酶能与缺陷piggyBac转座子协同使用。
2.1高活性piggyBac转座酶在制备基因代偿治疗所需试剂中的应用。
本发明高活性piggyBac转座酶在基因代偿的试剂应用的一个实施例中，将携带新型高活性piggyBac转座酶与携带凝血因子IX的缺陷piggyBac转座子的裸DNA各25μg与3mL乳酸林格氏缓冲液混合。随后将混合液通过液压尾静脉注射在7秒内快速注射入小鼠体内，转染肝脏。在注射后5天、30天和60天，分别通过尾静脉采取血样，加入肝素抗凝获得血浆样品。血浆中凝血因子IX水平由酶联免疫吸附试验ELISA(购自Abcam)测定，具体的实验条件为厂商所建议的条件。如图4所示，本发明的新型高活性piggyBac的转座酶相较于野生型piggyBac转座酶能更高效地介导治疗基因整合，持久稳定地提高血浆中凝血因子IX水平。
在另一些实施方式中，新型高活性piggyBac转座酶与携带治疗基因的缺陷piggyBac转座子的核酸通过纳米颗粒导入被治疗对象体内。
在另一些实施方式中，新型高活性piggyBac转座酶与携带治疗基因的缺陷piggyBac转座子的核酸可以被装入病毒载体。这里的病毒载体包括但不限于腺病毒、腺相关病毒，反转录病毒，慢病毒和单纯疱疹病毒。随后，对携带转座子系统的病毒进行包装，并感染导入被治疗对象体内。
在另一些实施方式中，新型高活性piggyBac转座酶与携带治疗基因的缺陷piggyBac转座子的核酸可以通过上呼吸道，肌肉注射，静脉注射导入被治疗对象体内。
在另一些实施方式中，新型高活性piggyBac转座酶与携带治疗基因的缺陷piggyBac转座子的核酸可以先行导入离体的成纤维细胞或血液细胞，包括：造血干细胞或各祖细胞，随后将细胞植入被治疗对象体内。
在另一些实施方式中，缺陷piggyBac转座子可携带的核酸片段为对治疗有价值的基因，包括但不限于腺苷脱氨酶，凝血因子VIII，β-球蛋白，血红蛋白，抗肌萎缩蛋白，α-抗胰蛋白酶，低密度蛋白受体，囊性纤维化跨膜通道调节因子，嵌合抗原受体，各类细胞因子，自杀基因和反义序列。
2.2基因无痕修复
piggyBac转座子插入靶位点的序列为四核苷酸的TTAA。piggyBac转座子在切离TTAA时一般不会改变原位点及原位点的附近序列，即所谓无痕转座。利用这一特点，piggyBac转座子系统可以与精准基因编辑工具，包括：锌指核酸酶ZFN，转录激活因子样效应物核酸酶TALEN和成簇常间隔短回文重复序列及相关核酸酶CRISPR/Cas9，相结合运用于致病基因突变无痕修复。
本发明高活性piggyBac转座酶应用于基因代偿治疗的一个实施例中，如图5所示，将编码精准基因编辑工具系统的核酸和携带缺陷piggyBac转座子及基因修复供体的模板核酸同时导入带致病基因突变的靶细胞。上面piggyBac转座子被置于修复供体基因组序列旁的TTAA位点内，并携带正向药物筛选标记，如:puromycin抗性基因，和反向药物筛选标记，如：TK，thymidine kinase基因。携带缺陷piggyBac转座子及基因修复供体的核酸通过同源重组被靶向导入基因组内，原致病基因突变被置换，正向药物筛选得到靶基因修复的细胞克隆。随后，导入新型高活性piggyBac转座酶将缺陷piggyBac转座子从TTAA处无痕切离，反向药物筛选得到致病基因突变无痕修复的细胞克隆。
3.转基因非人动物建立
本发明高活性piggyBac转座酶应用于转基因非人动物建立的一个实施例中，转基因小鼠可由携带转座子插入突变的受精卵产生获得，如图6所示，具体的步骤是：将编码新型高活性piggyBac转座酶和携带Katshka远红外荧光蛋白编码序列的缺陷piggyBac转座子的核酸，按摩尔比1：1的比例混合。取混合DNA样品5ng/μL，通过原核显微注射同时导入离体的小鼠受精卵的基因组内。用100mg/kg ketamine和10mg/kg xylazine麻醉假孕母鼠，手术打开腹腔，暴露输卵管。在输卵管内，植入10-15枚被注射的受精卵，随后进行手术缝合。在哺育得到的后代中，获得携带缺陷转座子插入的阳性小鼠。在绿色光照射下，阳性小鼠体表产生远红外荧光，可在荧光解剖镜下观察到。
在本发明应用于转基因非人动物建立的另一些实施例中，编码新型高活性piggyBac转座酶的核酸DNA可先在体外被反转录成信使RNA，随后与缺陷piggyBac转座子的核酸同时被显微注射入受精卵。
在本发明应用于转基因非人动物建立的另一些实施例中，转基因小鼠可由携带转座子插入突变的精原干细胞或胚胎干细胞产生获得。
在本发明应用于转基因非人动物建立的另一些实施例中，缺陷piggyBac转座子可携带的核酸片段包括但不限于启动子，调控元件，报告基因，基因编码序列，聚腺苷酸转录终止信号，基因敲低构建，基因捕获构建。
Claims (8)
1.一种piggyBac转座酶，其特征在于：
氨基酸位点165位的甘氨酸改变为半胱氨酸，或氨基酸位点282位的蛋氨酸改变为苏氨酸，或这两个位点同时发生上述改变。
2.如权利要求1所述的piggyBac转座酶，在制备介导缺陷piggyBac转座子转座插入HEK293细胞基因组的试剂中的应用。
3.如权利要求1所述的piggyBac转座酶在制备基因整合试剂中的应用。
4.如权利要求1所述的piggyBac转座酶，在制备无痕基因修复的试剂中的应用，其特征在于：
piggyBac转座酶为PBase(G165C/M282T)。
5.如权利要求1所述的piggyBac转座酶，在建立转基因非人动物中的应用，其特征在于：
包括将编码新型高活性piggyBac转座酶PBase(G165C/M282T)和携带Katshka远红外荧光蛋白编码序列的piggyBac转座子同时显微注射入小鼠受精卵内的步骤。
6.如权利要求1所述的piggyBac转座酶，在制备建立转基因非人动物的试剂中的应用。
7.如权利要求6所述的应用，其特征在于：所述试剂中还包含携带Katshka远红外荧光蛋白编码序列的piggyBac转座子。
8.如权利要求所述的高活性piggyBac转座酶在制备基因代偿治疗所需试剂中的应用，其特征在于：包括制备携带新型高活性piggyBac转座酶与携带凝血因子IX的缺陷piggyBac转座子的裸DNA的步骤。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910105753.1A CN111518785B (zh) | 2019-02-01 | 2019-02-01 | 一种高活性piggyBac转座酶及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910105753.1A CN111518785B (zh) | 2019-02-01 | 2019-02-01 | 一种高活性piggyBac转座酶及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111518785A true CN111518785A (zh) | 2020-08-11 |
| CN111518785B CN111518785B (zh) | 2024-02-27 |
Family
ID=71900451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910105753.1A Active CN111518785B (zh) | 2019-02-01 | 2019-02-01 | 一种高活性piggyBac转座酶及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111518785B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100287633A1 (en) * | 2009-02-26 | 2010-11-11 | Transposagen Bio | Hyperactive PiggyBac Transposases |
| US20110047635A1 (en) * | 2006-08-28 | 2011-02-24 | University of Hawail | Methods and compositions for transposon-mediated transgenesis |
| CN102421902A (zh) * | 2009-02-25 | 2012-04-18 | 约翰·霍普金斯大学 | Piggybac转座子变异及其使用方法 |
-
2019
- 2019-02-01 CN CN201910105753.1A patent/CN111518785B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110047635A1 (en) * | 2006-08-28 | 2011-02-24 | University of Hawail | Methods and compositions for transposon-mediated transgenesis |
| CN102421902A (zh) * | 2009-02-25 | 2012-04-18 | 约翰·霍普金斯大学 | Piggybac转座子变异及其使用方法 |
| US20100287633A1 (en) * | 2009-02-26 | 2010-11-11 | Transposagen Bio | Hyperactive PiggyBac Transposases |
Non-Patent Citations (1)
| Title |
|---|
| KOSUKE YUSA，ET AL: "A hyperactive piggyBac transposase for mammalian applications", PNAS, vol. 108, no. 4, 25 January 2011 (2011-01-25), pages 1531 - 1536 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111518785B (zh) | 2024-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11485959B2 (en) | Hyperactive piggybac transposases | |
| US20200017882A1 (en) | Engineering of humanized car t-cell and platelets by genetic complementation | |
| EP2971006A2 (en) | Reproducible method for testis-mediated genetic modification (tgm) and sperm-mediated genetic modification (sgm) | |
| US20160029604A1 (en) | Multiplex gene editing | |
| Sinzelle et al. | Generation of trangenic Xenopus laevis using the Sleeping Beauty transposon system | |
| US20190223417A1 (en) | Genetically modified animals having increased heat tolerance | |
| JP2018531003A6 (ja) | 向上した耐暑性を有する遺伝子改変動物 | |
| DK2124535T3 (en) | Transgenic pigs and processes for their production | |
| CN110177878B (zh) | 转基因动物和生物生产方法 | |
| Dehdilani et al. | Genetically engineered birds; pre-CRISPR and CRISPR era | |
| AU2016344144A1 (en) | Engineering of humanized kidney by genetic complementation | |
| JP7280643B1 (ja) | 遺伝子改変ブタの製造方法、樹立された体細胞、及び、遺伝子改変ブタ製造用原料 | |
| CN111518785A (zh) | 一种高活性piggyBac转座酶及其应用 | |
| Li et al. | Associated technologies for genome editing | |
| Kumari et al. | Transgenic animals in biotechnology | |
| Zimmer et al. | Gene targeting constructs: effects of vector topology on co-expression efficiency of positive and negative selectable marker genes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |